KHB(SZ:002022)2022-12-03 09:20Group 1: Company Strategy and Performance - The core strategy since 2017 is "product-centric and market-oriented," with 2018's operations aligning with this strategy [2] - Significant acquisitions in molecular diagnostics, including Suzhou Tianlong and Xi'an Tianlong, enhance product and technology positioning [2] - The biochemical business remains a major cash flow source, with a focus on optimizing resource allocation and integrating marketing teams [3] Group 2: Financial Highlights - Channel acquisitions contribute approximately 20% to total revenue, with net profit around 10% [4] - The company has obtained over 30 certifications for the Hitachi 008 system, which is expected to become a new growth point [3] Group 3: Future Outlook and Goals - The company aims to achieve industry-leading levels in key business areas over the next three to five years, with a focus on maintaining strategic execution [5] - The second phase of the equity incentive plan is expected to enhance company cohesion and support strategic deployment [3] Group 4: Market Trends and Challenges - The molecular diagnostics sector is identified as a high-growth area, with ongoing collaborations expected to yield significant results [4] - The company is cautiously exploring bundled procurement models, emphasizing long-term partnerships with hospitals [5]